Roxadustat Tablets Manufacturer in India | CKD Anemia Treatment Exporter

Product Overview
Key Features
Therapeutic Uses
Dosage Form Advantages

Roxadustat Tablets are oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) used for the treatment of anemia associated with chronic kidney disease (CKD). The medicine works by stimulating endogenous erythropoietin production, improving iron utilization, and enhancing red blood cell formation under controlled physiological pathways. Genliva Wellness LLP is a trusted Roxadustat Tablet Manufacturer in India offering high-quality nephrology and hematology formulations for domestic and international pharmaceutical markets.

Roxadustat is widely used in CKD-related anemia management, especially in patients undergoing dialysis or those who are not adequately responding to traditional iron or erythropoietin therapies. As a reliable Roxadustat Tablet Exporter from India, Genliva Wellness LLP supplies quality-assured pharmaceutical products to healthcare providers and distributors worldwide.

Roxadustat Tablets represent an advanced therapeutic approach to anemia management by addressing oxygen-sensing pathways and improving endogenous red blood cell production.

Roxadustat Tablets are formulated to regulate oxygen-sensing pathways and support erythropoiesis.

Contains Roxadustat as the active ingredient
Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)
Stimulates endogenous erythropoietin production
Enhances iron metabolism and utilization
Promotes red blood cell formation
Targets oxygen-sensing regulatory pathways

Roxadustat Tablets are used in the treatment of anemia associated with kidney disease.

Anemia of chronic kidney disease (CKD)
Dialysis-related anemia
Non-dialysis CKD anemia
Hemoglobin deficiency management
Nephrology supportive care
Erythropoiesis stimulation therapy

Roxadustat Tablets provide a novel mechanism for anemia correction.

Stimulates natural erythropoietin production
Improves iron utilization efficiency
Supports sustained hemoglobin increase
Reduces need for injectable ESA therapy
Targets physiological oxygen-sensing pathways
Provides advanced CKD anemia management approach